De-risking Drug Development | Episode 2: Focus on safety and efficacy and prove quickly that your product works
De-risking Drug Development is a five-part podcast series that explores the business-critical decisions that take place at each stage of the drug development process. We know that novel therapies often don’t meet their revenue expectations, but through informed decision-making, you can minimize risk and maximize the probability of commercial success.
In episode two we discuss the critical decision points in early phase development (phase I to IIa) that can ultimately determine the success of your product. Specifically, we discuss why drugs fail at this early stage, focusing on safety, tolerability and efficacy. We focus on the importance of integrated clinical development planning, with our experts' informed perspectives on regulatory, feasibility and early phase requirements. Our discussion covers how risk can be mitigated, and key takeaways that biotech leaders should - but often don't - consider in early phase development.
Episode 1: Determine how to drive value in pre-clinical development
Episode 2: Focus on safety and efficacy and prove quickly that your product works
Episode 3: Plan how to get to market quickly, post-proof of concept
Episode 4: Implement market launch strategy, pre-approval
Episode 5: Expand the use and value of your product over time
Related Insights
CTB Podcast
Pioneering oncology trials with AVEO Oncology
Mar 11, 2025
Case Study
Case Study Marketing Authorization Transfer
Nov 25, 2021
Article
Getting to ‘No’ fast is more important when you are small
Mar 4, 2022
Article
How biotechs can strengthen their value story with advanced analytics
Feb 15, 2022
Blog
Three Ways Early-Stage Companies Can Attract Investors
Feb 3, 2022
Podcast
Funding Biotech Innovation: How to Attract Investors
Jan 18, 2022
Article
How emerging biotechs can enter the Chinese market and prosper
Jan 18, 2022
Video
Biotech Showcase: Fireside Chat with Jamie Macdonald
Jan 3, 2022
Article
Three strategies for articulating a coherent product value story
Dec 18, 2021
Blog
Master Protocol Trials: What Are the Elements of Success?
Dec 1, 2021
Case Study
Case Study Lifecycle maintenance
Nov 25, 2021
Playbook
Insights from the 2022 R&D Innovation Survey
Feb 17, 2023
Related Insights
CTB Podcast
Pioneering oncology trials with AVEO Oncology
Mar 11, 2025
Case Study
Case Study Marketing Authorization Transfer
Nov 25, 2021
Article
Getting to ‘No’ fast is more important when you are small
Mar 4, 2022
Article
How biotechs can strengthen their value story with advanced analytics
Feb 15, 2022
Blog
Three Ways Early-Stage Companies Can Attract Investors
Feb 3, 2022
Podcast
Funding Biotech Innovation: How to Attract Investors
Jan 18, 2022
Article
How emerging biotechs can enter the Chinese market and prosper
Jan 18, 2022
Video
Biotech Showcase: Fireside Chat with Jamie Macdonald
Jan 3, 2022
Article
Three strategies for articulating a coherent product value story
Dec 18, 2021
Blog
Master Protocol Trials: What Are the Elements of Success?
Dec 1, 2021
Case Study
Case Study Lifecycle maintenance
Nov 25, 2021
Playbook
Insights from the 2022 R&D Innovation Survey
Feb 17, 2023